Could Diabetes Drugs Offer New Hope for Addiction Treatment? What the Latest Research Shows

Diabetes and obesity medications are showing unexpected promise in reducing substance cravings across alcohol, opioids, cocaine, and nicotine, according to major new research. The findings have sparked renewed interest in how these drugs might reshape addiction treatment, though UK health regulators emphasise that much more research is needed before any change to clinical practice.

GLP-1 receptor agonists—drugs commonly known by brand names including Ozempic and Saxenda—work by mimicking a natural hormone that helps regulate blood sugar and appetite. They are currently licensed in the UK only for managing type 2 diabetes and obesity. What has captured scientists’ attention is an unexpected side effect: patients taking these medications report a sudden loss of craving for alcohol, nicotine, and other substances after years of struggling with addiction.

The Research Behind the Headlines

A landmark study published in the British Medical Journal examined data from more than 606,000 US veterans with type 2 diabetes over three years. Researchers, led by Dr Ziyad Al-Aly from Washington University School of Medicine, compared those prescribed GLP-1 medications with those given a different diabetes drug (an SGLT-2 inhibitor) that does not affect the brain’s reward pathways.

The results were striking. Among people without existing substance use disorders, those taking GLP-1 drugs showed a 14 to 25 per cent reduced risk of developing addictions to major substances—alcohol, cannabis, cocaine, nicotine, and opioids. This translated to roughly six or seven fewer new diagnoses per 1,000 users over three years.

For people already living with substance use disorders, the findings were even more significant. GLP-1 use was associated with a 40 per cent reduction in overdoses, a 50 per cent reduction in drug-related deaths, and a 30 per cent reduction in emergency department visits related to substance use—representing approximately 12 fewer serious harm events per 1,000 users.

The consistency of results across multiple substance types rather than a single drug suggests these medications may work by dampening craving itself—what researchers call “drug noise”—rather than targeting specific addictions individually.

How Might These Drugs Work?

The biological explanation lies in the brain’s reward circuitry. GLP-1 receptors are abundant in the mesolimbic dopamine system, the neural pathway responsible for reinforcing cravings and reward-seeking behaviour. Addictive substances—from alcohol to opioids—exploit this same pathway to create dependence.

At therapeutic doses, GLP-1 medications cross the blood-brain barrier and appear to modulate dopamine signalling. This may explain why patients report a general quieting of intense cravings across multiple substance types, similar to how these drugs suppress persistent thoughts about food—described as “food noise.”

Important Caveats for UK Patients

Whilst the research is encouraging, it is crucial to emphasise that GLP-1 medications are not licensed or approved for treating addiction in the UK. The National Institute for Health and Care Excellence (NICE) has not issued any guidance recommending these drugs for substance use disorders, and they should not be considered established therapies for addiction at present.

The UK evidence review emphasises that current research remains preliminary. Most human studies are observational—meaning researchers analysed existing data rather than conducting randomised controlled trials, which cannot definitively establish cause and effect. Animal studies have shown promising effects, but translating this to human addiction treatment requires much more rigorous investigation.

These medications should only be used for addiction within clinical trials or specialist research settings. Any use outside these contexts would be off-label and without established safety and efficacy data specific to addiction treatment.

Current Treatment Remains the Standard

Evidence-based addiction treatments—including psychological interventions such as cognitive behavioural therapy, mutual support groups, and licensed pharmacotherapies—remain the cornerstone of UK addiction care. The UK Health Security Agency and NHS services continue to recommend these established approaches as the standard of care.

Researchers acknowledge that whilst the theoretical mechanisms are plausible and initial signals are promising, larger randomised controlled trials are essential before GLP-1 medications could ever be considered for addiction treatment in clinical practice.

What This Means for Kent Residents

For people in Kent struggling with substance use, current support remains available through established NHS pathways. Kent and Medway NHS Trust provides comprehensive addiction services, including structured psychological therapies, medication-assisted treatment, and harm reduction support. GPs can refer patients to specialist substance misuse services, and individuals can also contact their local integrated drug and alcohol service directly.

Whilst these emerging findings are scientifically fascinating, they represent early-stage research rather than an imminent shift in clinical practice. Anyone considering addiction treatment should speak with their GP or contact specialist services to discuss evidence-based options currently available. The research does, however, highlight how understanding brain chemistry could unlock new therapeutic approaches—offering hope that future treatments may provide additional tools in addressing the profound public health challenge of substance addiction.

Key Takeaways

• GLP-1 medications show promise in reducing substance cravings across multiple drug types in preliminary research
• A major study found 6–7 fewer new addiction diagnoses and 12 fewer serious harm events per 1,000 users
• GLP-1 drugs are not approved for addiction treatment in the UK and remain licensed only for diabetes and obesity
• Current evidence-based addiction treatments remain the standard of care in the NHS
• Further rigorous randomised trials are needed before clinical recommendations can change

What This Means for Kent Residents

If you or someone you know is struggling with substance use in Kent, established NHS support remains your first port of call. The Kent and Medway integrated drug and alcohol service provides evidence-based treatment including psychological therapy, medication support, and harm reduction. Speak to your GP for a referral, or contact your local substance misuse service directly. Whilst this emerging research is encouraging for the future, today’s proven treatments remain your most reliable option.